類器官研究中的細胞因子

類器官研究中的細胞因子選擇與應用李田子,Ph.D.

高級產品經理北京義翹神州科技股份有限公司09-2024義翹神州CONTENT類器官培養(yǎng)的關鍵細胞因子“配方”1經類器官培養(yǎng)驗證的細胞因子2義翹神州類器官培養(yǎng)的關鍵細胞因子“配方”01義翹神州類器官研究-市場情況義翹神州√√√√√Homan./10.1002/adbi.202200334HanbyeolLee;etal./10.51335/organoid.2021.1.e11.Source:終端客戶可能應用Biotchenology&Pharmaceuticalindustries主要用于建立類器官模型和類器官芯片以及基于模型的藥物開發(fā)，藥敏反應等Academic&ResearchinstitutesHospitals&DiagnosticCenters類器官研究-研究進展和潛在應用義翹神州Source:NCBI-PubMedCentralhttps://ClinicalTBasicresearchBiobankingPrecisionmedicine-Responsetodrugs-ResourcesforregenerativemedicinecoupledwithgeneticengineeringDiseasemodeling-Mechanismsofhumandiseases-InheritablegeneticdisordersDrug-screeninganalysesJihoonKim;etal./10.1038/s41580-020-0259-3.類器官研究-創(chuàng)新模型2024年8月14日,Nature刊發(fā)了一篇關于具有自體組織駐留免疫系統的腸道類器官（IIOs）模型傳統的腸道類器官主要關注上皮細胞的分化和功能，而未將免疫系統納入其中炎癥性腸?。↖BD）和癌癥等疾病中，免疫反應會影響疾病進展和治療效果文獻中建立的類器官可能能更準確地表現出腸道病生理的狀態(tài)義翹神州TimothyRecaldinetal./10.1038/s41586-024-07791-5.SchematicoverviewofestablishmentofautologousIIOs.腸道類器官-藥物篩選應用場景疾病研究題目臨床#藥物篩選結直腸癌ProspectiveObservationontheAccuracyofinVitroScreeningofColorectalCancerChemotherapyDrugsBasedonOrganoids-ona-chipNCT04996355TheCultureofAdvanced/Recurrent/MetastaticColorectalCancerOrganoidsandDrugScreeningNCT05304741Patient-derivedOrganoidsofRAS/RAFWild-typeMetastaticRightColonCancertoTesttheSensitivityandClinicalConsistencyofCombinedTreatmentofCetuximab.NCT04906733AProspectiveMulticenterRandomizedControlledTrialoftheClinicalEfficacyofNeoadjuvantTherapyBasedonOrganoidsDrugSensitivityVersusEmpiricalNeoadjuvantTherapyintheTreatmentofAdvancedRectalCancerNCT05352165義翹神州QinyingWang;etal./10.1038/s41392-022-01194-6.RSPO-1EGFNogginWnt腸道類器官激活小腸隱窩的Wnt信號協助小腸增殖隱窩數量增多維持腸道干細胞義翹神州ToshiroSato;etal./10.1053/j.gastro.2011.07.050.腸道類器官培養(yǎng)-主要細胞因子Figure.Human-derivedorganoids類器官研究-相關細胞因子BrainBreastLungProstatePancreaticHeartIntestinalGastricLiverEGFEGFEGFEGFEGFEGFFGF2FGF2FGF2FGF2FGF2FGF2FGF2FGF7TGFB1FGF10FGF10FGF10FGF10FGF10FGF10FGF10NOGNOGNOGNOGNOGNOGNOGNOGINHBAINHBAINHBAINHBAHGFRSPO1RSPO1RSPO1RSPO1RSPO1RSPO1RSPO1OSMDKK1DKK1GDNFLIF義翹神州OVARYBRAINBREASTLUNGSKIDNEYBLADDERPROSTATEEYESINNEREARESOPHAGUSSTOMACHINTESTINEandCOLONLIVERPANCREASBenedettaArtegiani;etal./10.1093/hmg/ddy187.經類器官培養(yǎng)驗證的細胞因子02義翹神州細胞因子產品線特點概述GMP認證書250+細胞因子類分子，800+細胞因子類產品按照ISO9001:2015和ISO13485:2016質量管理體系要求進行生產涉及免疫細胞培養(yǎng)、干細胞研究、類器官培養(yǎng)等熱門應用領域覆蓋生長因子、趨化因子、干擾素、白介素、淋巴因子等嚴格質控造就更優(yōu)細胞活性高批間一致性高純度（20+GMP級細胞因子）義翹神州2024年值得關注的生長因子供應商細胞因子產品設計種屬多：Human、Mouse、Monkey等，盡可能滿足不同的動物實驗模型傾向于無標簽或者小標簽真核或者原核表達系統低內毒素活性有競爭力應用場景數據展示義翹神州多種屬：Human、Mouse、Monkey等，盡可能滿足不同動物實驗模型的需求義翹神州小鼠膀胱類器官培養(yǎng)MouseBladderOrganoidsafter14daysinculture25ng/mLofRecombinantMouseKGF/FGF-7Protein(50394-M07E)wasusedfor2weeksinBMEsubmergedinmousebladdermedia.DataprovidedbyDr.YinatWashingtonUniversity,St.Louis,MO.經過14天的培養(yǎng)：細胞因子產品設計LPS處理的胚狀體中胚層的生物標志物會消失且不能分化成有功能的成骨細胞LPS處理的胚狀體會出現凋亡的現象義翹神州KavithaSivasubramaniyan;etal./10.2217/1746073.細胞因子產品設計低內毒素Panel(A)showsnormal5-day-oldembryoidbodiesand(B)shows5-day-oldembryoidbodiesexposedtolipopolysaccharidesfor48h.Picturewereacquiredat10×magnifications.Cometassayshowingthedegreeofapoptosisinducedincontrolandlipopolysaccharides-treatedembryoidbodies.CD14+

monocytes

were

differentiated

into

immature

DCs

by

GM-CSF(GMP-10015-HNAH)

and

IL4(GMP-11846-HNAE)

for

6

days.

DCs

were

matured

by

TNF(GMP-10602-HNAE)

for

2

days.Immature

DCsMature

DCs義翹神州細胞因子產品設計應用場景數據展示-1：免疫細胞應用場景義翹神州產品詳情頁下拉：點開產品詳情頁：細胞因子產品設計應用場景數據展示-2：類器官應用場景iPSC-derivedhumanvascularorganoids(Day7)wereculturedwithFGF2(10014-HNAE),VEGF165(11066-HNAH),EGF(10605-HNAE).Redarrowsrepresentvascularorganoids.Imagetakenat10xmagnification.DataprovidedbyDr.WangatSchoolofBasicMedicalSciencePekingUniversity義翹神州活性比較數據批間一致性數據MeasuredinacellproliferationassayusingBalb/C3T3mouseembryonicfibroblasts.EGF

(Cat#:10605-HNAE)義翹神州批次1義翹神州批次2義翹神州批次3國外知名品牌義翹神州批次1義翹神州批次2高純度（≥95%）FGF2(Cat#:10014-HNAE)VEGF165(Cat#:11066-HNAH)血管類器官培養(yǎng)類器官培養(yǎng)相關產品數據高純度（≥95%）類器官相關產品的引用文獻義翹神州文獻名稱(年份)-類器官類型影響因子所用貨號HumanearlysyncytiotrophoblastsarehighlysusceptibletoSARS-CoV-2infection(2022)-滋養(yǎng)層類器官11.710463-HNAS(HGF);11083-HNAS(RSPO1)Single-celltranscriptomicsrevealscellatlasandidentifiescyclingtumorcellsresponsibleforrecurrenceinameloblastoma(2024)-成釉細胞瘤類器官10.810014-HNAE(FGF2)CUL4B-DDB1-COP1-mediatedUTXdownregulationpromotescolorectalcancerprogression(2023)-結直腸癌類器官9.411083-HNAS(RSPO1);50688-M02H(NOG);50482-MNCH(EGF);10573-HNAE(FGF10)FeedbackactivationofEGFR/wild-typeRASsignalingaxislimitsKRASG12DinhibitorefficacyinKRASG12D-mutatedcolorectalcancer(2023)-結直腸癌類器官6.911083-HNAS(RSPO1);50688-M02H(NOG);50482-MNCH(EGF)EvaluationofB7-H3TargetedImmunotherapyina3DOrganoidModelofCraniopharyngioma(2022)-顱咽管瘤類器官4.810605-HNAE(EGF);10573-HNAE(FGF10)2022~2024類器官相關引用文獻數量滋養(yǎng)層類器官培養(yǎng)-文獻中產品應用案例擴增潛力干細胞-滋養(yǎng)層干細胞來源的滋養(yǎng)層類器官義翹神州50ng/mLHumanHGF(SinoBiological,10463-HNAS)50ng/mLHumanEGF80ng/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)中用到的細胞因子100ng/mLHumanFGF2DegongRuan;etal./10.1016/j.xcrm.2022.100849.滋養(yǎng)層類器官類器官培養(yǎng)相關產品數據義翹神州活性比較數據批間一致性數據Measuredbyitsabilitytoinduceactivationof?cateninresponseinaTopflashLuciferaseassayusingHEK293Thumanembryonickidneycells.RSPO1(Cat#:11083-HNAS)國外知名品牌義翹神州義翹神州批次1義翹神州批次2義翹神州批次3活性比較數據批間一致性數據MeasuredbyitsabilitytoneutralizeTGF-betamediatedinhibitiononMv-1-Lucellproliferation.HGF(Cat#:10463-HNAS)義翹神州國外知名品牌義翹神州批次1義翹神州批次2義翹神州批次3腸道類器官培養(yǎng)-文獻中產品應用案例1義翹神州AdvancedDMEM/F12medium50ng/mLMouseEGF(SinoBiological,50482-MNCH)100ng/mLMouseNoggin(SinoBiological,50688-M02H)50mg/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)主要組成結直腸癌組織分離培養(yǎng)包埋在Matrigel中接種到12孔板上添加類器官培養(yǎng)基每2~3天更換新鮮培養(yǎng)基結直腸癌類器官用于：藥敏試驗藥物作用機制研究Fenget/10.1038/s41388-023-02676-9.結直腸癌類器官--結直腸癌患者治療效果的研究腸道類器官培養(yǎng)-文獻中產品應用案例2義翹神州AdvancedDMEM/F12medium50ng/mLMouseEGF(SinoBiological,50482-MNCH)100ng/mLMouseNoggin(SinoBiological,50688-M02H)500ng/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)主要組成結直腸癌組織分離培養(yǎng)包埋在Matrigel中接種到48孔板上添加類包含藥物的培養(yǎng)基每3天更換新鮮培養(yǎng)基結直腸癌類器官用于：疾病研究藥物作用機制研究DakuiLuoet/10.1186/s40164-023-00440-z.100ng/mLHumanFGF10(SinoBiological,10573-HNAE)結直腸癌類器官--疾病研究不同時間點顱咽管瘤類器官的形態(tài)

腦類器官培養(yǎng)-文獻中產品應用案例義翹神州10ng/mLHumanFGF10(SinoBiological,10573-HNAE)10ng/mLHumanEGF(SinoBiological,10605-HNAE)培養(yǎng)中用到的細胞因子Xiao-YanTang;etal./10.1038/s41392-022-01024-9.腦腫瘤類器官類器官培養(yǎng)相關產品數據義翹神州CellproliferationassayusingBaF3mousepro-BcellstransfectedwithhumanFGFR2b.FGF10(Cat#:10573-HNAE)活性比較數據國外知名品牌義翹神州高純度（≥95%）CellproliferationassayusingBaF3mousepro-BcellstransfectedwithhumanFGFR2b.FGF7/KGF(Cat#:10210-H07E)活性比較數據國外知名品牌義翹神州高純度（≥95%）類器官培養(yǎng)相關產品數據義翹神州

InhibitproliferationofMPC-11cells.>1000U/mg活性比較數據義翹神州國外知名品牌

GMP級HumanActivinA

(Cat#:GMP-10429-HNAH)高純度（≥95%）CellproliferationassayusingTF-1humanerythroleukemiccells.>30,000Units/μg批間一致性數據義翹神州批次1義翹神州批次2

GMP級HumanOSM(Cat#:GMP-10452-HNAH)高純度（≥95%）經不同類器官培養(yǎng)驗證的細胞因子義翹神州人腸癌類器官人結直腸類器官HumanintestinalcancerorganoidswereculturedwithRSPO1(11083-HNAS),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnologyHumancolorectumorganoidswereculturedwithRSPO1(11083-HNAS),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnology.義翹神州人肺癌類器官人肺類器官HumanlungcancerorganoidswereculturedwithFGF2(10014-HNAE),FGF4(16043-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumanlungorganoidswereculturedwithFGF2(10014-HNAE),FGF4(16043-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經不同類器官培養(yǎng)驗證的細胞因子義翹神州人肝癌類器官人膽管癌類器官HumanlivercancerorganoidswereculturedwithFGF2(10014-HNAE),HGF(10463-HNAS),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),TGFB1(10804-HNAC),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumancholangiocarcinomasorganoidswereculturedwithFGF2(10014-HNAE),HGF(10463-HNAS),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經不同類器官培養(yǎng)驗證的細胞因子義翹神州人腎癌類器官人腎類器官HumankidneycancerorganoidswereculturedwithFGF2(10014-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumankidneyorganoidswereculturedwithFGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS),HGF(10463-HNAS),FGF4(16043-HNAE).(Routinelytested).DataprovidedbyD1MedicalTechnology.經不同類器官培養(yǎng)驗證的細胞因子義翹神州人胃癌類器官人胃類器官HumangastriccancerorganoidswereculturedwithEGF(50482-MNCH),

FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnologyHumanstomachorganoidsorganoidswereculturedwithEGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經不同類器官培養(yǎng)驗證的細胞因子義翹神州人卵巢癌類器官人小腸類器官HumansmallintestinalorganoidswereculturedwithIL22(13059-HNAE),FGF10(10573-HNAE),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnology.Humanovarianorg